




**Simposio  
Regional 2:**


**20/11  
Salón: Río IV  
10:30 a 12:00**



**Coordinador:**  
**Diego Villa**

**Secretario:**  
**Alfredo Morán**

**Disertante:**  
**María Laura Baez  
Pannocchia**



## Servicio Neumonología


Pacientes COVID-19 convalecientes



- Características Clínicas
  - Evolución




# MATERIAL Y MÉTODO




- Estudio retrospectivo, observacional y descriptivo con muestreo estratificado de pacientes COVID-19 convalecientes.
- Abril 2021 - Junio 2021.
- Plataforma de Google Form:
  - Sociodemográficas
  - Comorbilidades
  - Síntomas
  - Gravedad
  - Datos Radiográficos
  - Estado de vacunación contra COVID-19.

# MATERIAL Y MÉTODO



<b>Enfermedad No Complicada</b>	Ausencia de comórbidas e infiltrados radiológicos $SO_2 > 95\%$ $FI O_2 0.21$
<b>Neumonía Leve</b>	<60 años - Ausencia de comórbidas - Compromiso radiológico Unilateral $SO_2 > 95\%$
<b>Neumonía Moderada</b>	$\geq 60$ edad - Comórbidas - Compromiso radiológico Bilateral $SO_2 \leq 95\%$
<b>Neumonía Grave</b>	ATS/IDSA: 1 criterio mayor - 3 criterios menores




**Post COVID-19 Prolongado**

Persistencia de síntomas 3- 12 semanas


**Post COVID-19 Crónico**

Persistencia de síntomas > 12 semanas.





107 PACIENTES

## GÉNERO




## EDAD






107 PACIENTES


## COMÓRBIDAS RESPIRATORIAS






107 PACIENTES

## COMÓRBIDAS









107 PACIENTES

## LUGAR CONTAGIO




DIAGNÓSTICO RT-PCR SARS-CoV-2: 86%




107 PACIENTES

- GRAVEDAD




- TIPO DE ATENCIÓN: Ambulatorio (57%), Sala General (39.3%), UPI (3.7%).
- OXIGENOTERAPIA: en agudo 44.9%, al alta 19.6%.





107 PACIENTES

## VACUNACIÓN PRE-ENFERMEDAD




- 94.7% con 1 dosis






## DURACIÓN DE SÍNTOMAS

Inicio	<10 días	10-21 días	>3 semanas	>12 semanas
<b>Astenia (67.3%)</b>	27 (35.5%)	21 (27.6%)	25(32.9%)	3 (3.9%)
<b>Tos (66.4%)</b>	32 (45.1%)	20 (28%)	14 (19.7%)	5 (7%)
<b>Artromialgias (58.9%)</b>	29 (42.6%)	20 (29%)	17 (25%)	2 (2.9%)
<b>Fiebre (55.1%)</b>	50 (87.7%)	7 (12.3%)		
<b>Disnea (54.1%)</b>	11 (19.3%)	12 (21.1%)	26 (45.6%)	8 (14%)
<b>Cefalea (53.3%)</b>	39 (75%)	4 (7.7%)	7 (13.5%)	2 (3.8%)
<b>Congestión Nasal (42.1%)</b>	27 (57.4%)	10 (21.3%)	7 (14.9%)	3 (6.4%)
<b>Anosmia (39.3%)</b>	25 (65.8%)	4 (10.5%)	8 (21.1%)	1 (2.6%)
<b>Ageusia (35.5%)</b>	20 (55.6%)	4 (11.1%)	11 (30.6%)	1 (2.8%)
<b>Odinofagia (33.6%)</b>	29 (82.9%)	3 (8.6%)	3 (8.6%)	
<b>Diarrea (33.6%)</b>	31 (88.6%)	4 (11.4%)		
<b>Dolor Torácico (28%)</b>	13 (46.4%)	10 (35.7%)	5 (17.9%)	
<b>Febrícula (23.4%)</b>	25 (78.1%)	5 (15.6%)	2 (6.3%)	
<b>Palpitaciones (21.5%)</b>	13 (56.5%)	6 (26.1%)	4 (17.4%)	





107 PACIENTES

## SÍNDROME POST COVID-19




## INTERVALO FIS – CONTROL AMBULATORIO






107 PACIENTES

## TIPO DE LESIÓN TC TÓRAX




- Localización bilateral: 96.7%
- Distribución Periférica Subpleural: 75.4%
- Afección Multilobar: 93.3%
- Afección Campos Pulmonares Inferiores: 68.9%

# CONCLUSIÓN



- **Sexo:** distribución homogénea.
- **Edad promedio:** 50 años
- **Obesidad, HTA y Asma**
- **40% de población fumadora**
- **Contagio por contacto estrecho familiar conviviente.**





- Síntomas al inicio de la enfermedad:  
Astenia y Tos.
- Síndrome post COVID-19 ( 74,75% )
  - Prolongado: Disnea, Astenia y Ageusia
  - Crónico: Disnea, Tos y Congestión nasal,
- Patrón Tomográfico: Vidrio esmerilado bilateral periférico con predominio en lóbulos inferiores